前列腺癌放疗中使用SpaceOAR水凝胶相关的主要并发症与不良事件
基于MAUDE数据库2015年1月至2023年5月的数据,共识别981份报告、990例SpaceOAR相关不良事件。装置故障最常见(626例),患者伤害350例,死亡5例;CTCAE≥3级事件123例(13.1%)。作者认为部分事件比临床试验报告更严重,需持续上市后监测。
要点
- 装置故障最常见(626例),装置定位问题686例,疼痛为最常见患者问题(216例)。
- 脓肿和瘘管各报告91例;放疗开始前发生的不良事件35例(22.4%)。
- CTCAE 1级470例(50.2%)、2级344例(36.7%)、≥3级123例(13.1%)。
核心结论
- 识别到多份SpaceOAR相关不良事件报告,许多事件比临床试验报告更为严重。
- SpaceOAR使用广泛提示这些事件罕见,但数据强调需要持续上市后监测。
研究设计与样本
- 分析制造商与用户设施设备体验(MAUDE)数据库中2015年1月至2023年5月的SpaceOAR相关不良事件报告。
- 记录每份报告的事件类型、相关装置与患者问题、事件描述、事件发生时间及按CTCAE 5.0分级的严重程度。
- 2015年至2022年共售出206619个SpaceOAR装置;2015年1月至2023年5月识别981份报告,描述990例SpaceOAR相关不良事件。
主要发现
- 装置故障为最常见事件类型(626例),其次为患者伤害(350例),死亡报告5例。
- 装置定位问题为最常见装置问题(686例);疼痛为最常见患者问题(216例)。
- 装置相关脓肿和瘘管各报告91例。
- 相关不良事件中35例(22.4%)发生在放疗开始前,提示装置而非放疗 responsible。
- CTCAE 1级470例(50.2%)、2级344例(36.7%)、≥3级123例(13.1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the prevalence and severity of SpaceOAR-related adverse events using the Manufacturer and User Facility Device Experience (MAUDE) database. METHODS: We analyzed SpaceOAR-related adverse event reports in the Manufacturer and User Facility Device Experience (MAUDE) database from January 2015 to May 2023. For each report, the event type, associated device and patient problems, event description, event timing, and event severity stratified by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE) grading system were recorded. RESULTS: From 2015 to 2022, 206,619 SpaceOAR devices were sold. From January 2015 to May 2023, we identified 981 reports describing 990 SpaceOAR-related adverse events. Malfunctions were the most common event type (N = 626), followed by patient injuries (N = 350) with few reported deaths (N = 5). Device positioning problems were the most frequent device issue (N = 686). Pain was the most reported patient problem (N = 216). Abscesses and fistulas related to the device were each reported in 91 events. A noteworthy portion of relevant adverse events occurred before the initiation of radiation (N = 35, 22.4%), suggesting the device, rather than the radiation, was responsible. In total, 470 (50.2%) and 344 (36.7%) of the adverse events were CTCAE grade 1 and 2, respectively. There were 123 (13.1%) events that were CTCAE grade ≥3. CONCLUSION: We identified multiple reports of SpaceOAR-related adverse events, many of which are more serious than have been reported in clinical trials. While SpaceOAR use is common, suggesting these events are rare, these data highlight the need for continued postmarket surveillance.
引用
- Millot JC, Arenas-Gallo C, Silver E, et al. Major Complications and Adverse Events Related to Use of SpaceOAR Hydrogel for Prostate Cancer Radiotherapy. Urology. 2024. PMID: 38458325. doi:10.1016/j.urology.2023.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。